EDIT News
Archived Headlines
- US IPO Weekly Recap: Two big biotechs break the ice as the first IPOs of 2016 trade up 02/05/16
- First two IPOs of 2016 trade up; IPO market continues its 3-year biotech run 02/03/16
- Editas Medicine prices IPO at $16, the low end of the range 02/02/16
- Week ahead: Biotechs could snap IPO drought 01/29/16
- Editing your genes: Editas Medicine sets terms for $100 million IPO 01/25/16
See more
Bigger and better: 2016 IPOs that raised more than $100 million are up over 30%
The 21 IPOs this year that have raised raised over $100 million have delivered investors an average return of 32%, including a first-day pop of 14% and an additional 14% in the aftermarket. Most notably, only one IPO in this group currently trades below issue,...read more
Gene editing biotech Intellia Therapeutics files for a $120 million IPO
Intellia Therapeutics, which is developing gene editing therapies using CRISPR/Cas9 technology, filed on Monday with the SEC to raise up to $120 million in an initial public offering. Fellow CRISPR gene editing biotech Editas Medicine (EDIT) went public...read more
Renaissance Capital's 1Q16 US IPO Market Review
The US IPO market in the 1Q16 hit its lowest levels since the depths of the financial crisis in 2008/2009. Not a single deal priced outside of the health care sector, where eight deals managed to raise $0.7 billion thanks to substantial buying by their existing...read more
Biotechs lean heavily on insider buying to complete quasi-IPOs
Accounting for 100% of the four IPOs so far this year, biotechs appeared to be the one sector able to generate demand from public investors. But demand is weaker than...read more